Tinkelman D G, Vanderpool G E, Carroll M S, Lotner G Z, Spangler D L
Ann Allergy. 1983 Jun;50(6):398-401.
The purpose of this study was to compare nebulized terbutaline 5 mg vs. subcutaneous epinephrine (1/1000, 0.3 cc) in the treatment of acute exacerbations of asthma in adult patients. Patients with a known diagnosis of asthma, who presented to the investigators in acute respiratory distress, without any previous adrenergic agents for six hours, were the subjects for this study. There were 33 patients enrolled in the study between 16 and 64 years of age. The results indicate both treatment groups gave significant increases in pulmonary function at all times when compared to baseline (p less than 0.001). Nebulized terbutaline and subcutaneous epinephrine appeared equally effective in the treatment of acute exacerbations of asthma, without significant differences in bronchodilator effectiveness or side effects.
本研究的目的是比较雾化吸入5毫克特布他林与皮下注射肾上腺素(1/1000,0.3毫升)治疗成年哮喘患者急性加重期的效果。已知患有哮喘且在急性呼吸窘迫中前来就诊、在过去6小时内未使用过任何肾上腺素能药物的患者作为本研究对象。共有33名年龄在16至64岁之间的患者纳入该研究。结果表明,与基线相比,两个治疗组在所有时间点的肺功能均有显著改善(p<0.001)。雾化吸入特布他林和皮下注射肾上腺素在治疗哮喘急性加重期方面似乎同样有效,在支气管扩张效果或副作用方面无显著差异。